Menu
Step 1
Learning about TRACK begins at home.
After providing initial information, interested patients will have an introductory phone call with TargetCancer Foundation (TCF) study staff to discuss TRACK and confirm eligibility, and then have the option to fully consent to the study via an online consent process.
Step 2
TCF takes it from there.
Once a patient enrolls, the TCF study team will reach out to the treating institutions or medical offices to secure medical records, and also facilitate comprehensive genomic profiling (CGP) of tissue and blood.
Step 3
Recommendations provided.
Comprehensive genomic profiling reports on tissue and blood are returned to the TCF study team and the patient's treating physician. The TRACK Virtual Molecular Tumor Board, composed of field-leading rare cancer experts, convenes to review the reports and other data and provide treatment recommendations to the patient’s treating physician.
Step 4
Ongoing engagement.
Over the course of the following year, the TCF study team will collect updated study-related medical information from each patient. Patients will also be asked to provide additional blood samples for repeated CGP to identify new alterations which could potentially drive additional treatment recommendations.
Learn more about TRACK.
Contact us